S 38844

Drug Profile

S 38844

Alternative Names: S-38844

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Servier
  • Class Cardiovascular therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure
  • No development reported Cardiovascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in Germany (PO, Controlled release)
  • 01 Jun 2015 IRIS completes a phase II clinical trials in Heart failure in Hungary, Belgium, Slovakia, Estonia, Lithuania and Latvia (PO) (EudraCT2013-003000-39)
  • 01 Mar 2014 Phase-II clinical trials in Heart failure in Hungary (PO) (EudraCT2013-003000-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top